Dimensional Fund Advisors LP Purchases 302,087 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX)

Dimensional Fund Advisors LP grew its position in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 83.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 662,776 shares of the company's stock after acquiring an additional 302,087 shares during the quarter. Dimensional Fund Advisors LP owned about 0.62% of Tango Therapeutics worth $2,048,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Tango Therapeutics in the fourth quarter valued at $33,000. Teacher Retirement System of Texas raised its stake in shares of Tango Therapeutics by 35.8% in the fourth quarter. Teacher Retirement System of Texas now owns 14,544 shares of the company's stock valued at $45,000 after acquiring an additional 3,831 shares during the period. Sequoia Financial Advisors LLC purchased a new stake in shares of Tango Therapeutics in the fourth quarter valued at $45,000. Renaissance Technologies LLC purchased a new stake in shares of Tango Therapeutics in the fourth quarter valued at $66,000. Finally, Wells Fargo & Company MN raised its stake in shares of Tango Therapeutics by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 22,292 shares of the company's stock valued at $69,000 after acquiring an additional 7,599 shares during the period. Hedge funds and other institutional investors own 78.99% of the company's stock.

Tango Therapeutics Trading Up 16.9%

Shares of NASDAQ TNGX traded up $0.39 during mid-day trading on Tuesday, reaching $2.68. The company had a trading volume of 4,750,302 shares, compared to its average volume of 1,200,418. Tango Therapeutics, Inc. has a 52 week low of $1.03 and a 52 week high of $12.02. The business's 50-day moving average is $1.46 and its 200-day moving average is $2.49. The stock has a market cap of $290.17 million, a price-to-earnings ratio of -2.21 and a beta of 1.02.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.02). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. The business had revenue of $5.39 million for the quarter, compared to the consensus estimate of $6.73 million. As a group, equities research analysts forecast that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "buy" rating and issued a $13.00 price target on shares of Tango Therapeutics in a report on Monday, April 14th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $12.33.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.